Should High-Dose Interleukin-2 Still be the Preferred...

Cancer Biotherapy & Radiopharmaceuticals 2011 / 06 Vol. 26; Iss. 3

Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?

Dillman, Robert O., Barth, Neil M., VanderMolen, Louis A., Fong, Warren H., Mahdavi, Khosrow K., McClure, Stephanie E.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
26
Language:
english
Journal:
Cancer Biotherapy & Radiopharmaceuticals
DOI:
10.1089/cbr.2011.0969
Date:
June, 2011
File:
PDF, 172 KB
english, 2011
Conversion to is in progress
Conversion to is failed